藍帆醫療(002382.SZ):公司產品與Shockwave相比具有競爭力
格隆匯5月2日丨有投資者在投資者互動平台向藍帆醫療(002382.SZ)提問,“據國外新聞報道,波科預花費上百億美元收購美國IVL同行,請問公司如何看待自己IVL產品前景?”
藍帆醫療回覆稱,公司旗下冠狀動脈血管內碎石系統(IVL)上市前臨牀研究於2月9日啟動,進展符合預期。血管內鈣化是介入治療中非常棘手的病變,尤其是嚴重鈣化病變,被稱為“最硬的骨頭”或“最堅硬的堡壘”。一直以來,國內臨牀處理鈣化病變的方法主要是使用切割球囊、棘突球囊、旋磨等技術,但這些技術對於中膜深部鈣化、鈣化結節或重度鈣化卻“束手無策”。IVL術不僅對淺表鈣化有作用,也是唯一對深層鈣化有治療作用的技術,彌補了目前對於嚴重鈣化病變預處理技術的一些不足,真正做到血管擴張且無損傷。 公司的冠狀動脈血管內碎石系統(IVL)是自主研製開發,以輕便的可充電治療儀主機搭配操作簡單的導線接口及觸發裝置,使設備的安裝及整體操作均更易上手,公司產品與Shockwave相比具有競爭力。且首創性地採用了雙層結構的球囊材料,配合更小的profile,兼具了球囊導管柔順性及耐高壓能力的優勢——6atm的治療壓力能使球囊更加充分的貼壁,而高達20atm的爆破壓力則可提供聲壓治療後更高的後擴張能力,使血管預處理更充分。不僅如此, IVL導管還提供了豐富的型號規格選擇,包括12mm及15mm的球囊長度規格及最小2.00mm球囊直徑規格,更加精準地滿足複雜病變預處理的需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.